To our knowledge, this is the first clinical study to evaluate the effect of one-year semaglutide and sitagliptin treatment on serum IGFBP-1, IGFBP-3 and IGFBP-rp1 levels in overweight and obese patients with T2DM receiving metformin monotherapy. The gene discussed is IGFBP1; the disease is type 2 diabetes mellitus.